Bioanalysis, biomarker assay development, validation and sample analysis.
Drug development and manufacturing for biologics and small molecules, with integrated services from preclinical, clinical to commercial.
Best-in-class drug discovery products and services to identify and develop life-changing therapies.
Global insourcing solutions delivering on-site scientific and laboratory services.
Delivering safety, efficacy, biomarker, and pathology services, through a global network of CAP accredited laboratories.
Solutions from discovery through commercialisation.
With facilities in Europe, North America and Asia, we support clients in the pharma, diagnostics, food, agriculture, biotechnological and research markets.
Comprehensive BioPharma Product Testing: a leader in testing biologics, CGT, nucleic acid therapies, and small molecules from early developm…
With over 40 years of expertise and capabilities, Eurofins Medical Device Services offers comprehensive solutions across the entire medical…
Paul Morrissey, PhD, Senior Manager, Molecular & Cell Biology, Eurofins BioPharma Product Testing Ireland; Devakumar Sundaravinayagam, PhD, Senior Scientist, Biopharm
With the rapid expansion of GLP 1 receptor agonists in the treatment of obesity, type 2 diabetes, and metabolic disorders, the demand for highsensitivity, high-throughput bioanalytical platforms has never been greater. At Eurofins BioPharma Product Testing (BPT) Dungarvan, we have invested in the MESO QuickPlex® SQ 120MM, a state of the art electrochemiluminescence (ECL) detection system, to deliver fast, precise, and regulatory compliant testing for our global client base.
Why the MESO QuickPlex® SQ 120MM?
The MESO QuickPlex platform offers unmatched analytical performance for ligand binding assays and immunogenicity testing, making it ideal for the potency, pharmacokinetic (PK), and biomarker analysis of GLP 1 agonists. Its unique ECL technology provides:
Applications in GLP 1 agonist development Our Dungarvan team leverages the MESO QuickPlex SQ 120MM for:
This capability supports the development of multi-target therapies by enabling rapid, data-driven decision-making across both preclinical and clinical stages. It facilitates efficient candidate selection, dosing optimisation, and enhances translational predictability. Additionally, it contributes to mechanism-of-action research and adaptive trial design, ultimately improving development efficiency and success rates in treating complex diseases such as metabolic disorders.
Multiplexing strategy using U-PLEX and V-PLEX platforms
Multiplexing is a powerful analytical technique that enables the simultaneous quantitation of multiple analytes within a single well. This approach significantly enhances efficiency by reducing the number of plates required for analysis and conserving valuable sample volume, allowing up to 10 different analytes to be measured from just 20 μL of sample. At the Eurofins BPT’s Dungarvan site, we are adopting U-PLEX multiplexing technology to customise assay plates and optimise experimental conditions tailored to our specific analytical needs. Following this, we can validate to V-plex level, resulting in a validated kit-based assay that offers enhanced robustness and reproducibility for routine testing. This strategic approach is expected to streamline our workflows, improve data quality, and support high-throughput analysis in a cost-effective manner.
Partnering for Success
Whether you are advancing a first in human GLP 1 analogue or optimising a late stage clinical candidate, the MESO Quick-Plex SQ 120MM at Eurofins BPT Dungarvan offers the precision, speed, and compliance to accelerate client programs. Contact us at: EurofinsBPT-IE@bpt.eurofinseu.com